Viome Acquires Circulate Health, Closing the Loop Between Early Diagnostics, Precision Nutrition, and Treatment

Together, the companies give physicians one platform to measure biological insights, personalize care, and track outcomes across 200+ clinics.

The acquisition moves Viome closer to its goal of creating a connected precision-longevity platform that links biological measurement with personalized intervention and longitudinal outcomes.

“Acquiring Circulate is the latest step in giving patients not just answers, but precision intervention,” said Naveen Jain, founder of Viome.

Circulate Health delivers TPE through partner clinics staffed by specially trained nurses. While TPE has been used in hospitals for decades to treat autoimmune and neurological conditions, Circulate has developed protocols applying the procedure to longevity and chronic disease care.

Recent research has added to the company’s clinical focus. A 2026 Journal of Clinical Apheresis study reported measurable reductions in circulating microplastic particles following Circulate’s TPE procedure in patients with elevated baseline levels. A 2025 Aging Cell study reported an average 2.6-year reduction in biological age across a panel of molecular biomarkers.

Dr. Brad Younggren, Circulate’s co-founder and CEO, will become president of Viome Professional, the company’s newly formed clinical group.

“Precision plasma exchange alongside Viome’s molecular platform gives clinicians a broader, more credible way to practice longevity medicine today,” Younggren said.

The combined platform is intended to help clinicians move beyond one-time testing by connecting diagnostics, personalized interventions, clinical delivery, and outcome measurement. Viome said the platform can expand as additional tests, therapies, and technologies become available.

Founded in 2016, Viome develops molecular and AI-based technologies focused on the early detection and prevention of chronic disease, cancer, and aging.